Skip to main content

Korean Skin Rejuvenation: PRP, PRF, Exosomes & RF Microneedling Options Released

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Lydian Clinic in Seoul outlines differences, evidence limits, and risks of PRP, PRF, exosome boosters, and RF microneedling, helping international visitors compare skin-rejuvenation options before planning personalized treatment.

-- Lydian Cosmetic Surgery Clinic in Seoul has published educational guidance comparing PRP, PRF, exosome boosters, and RF microneedling, outlining how each option differs along with their evidence limitations and risks. The material is intended to help international visitors to Seoul understand how these treatments might fit within a personalized skin-rejuvenation plan.

More information is available at https://www.lydianclinic.com/blog/kim-kardashian-prp-prf-treatment-korea/

International patients researching skin rejuvenation in Seoul frequently encounter overlapping terminology, since PRP, PRF, and exosomes are often described in similar marketing language despite meaningful differences. Understanding the source, mechanism, and evidence behind each option allows patients to set realistic expectations before committing to a treatment plan.

PRP and PRF are both prepared from a patient's own blood, though their structures differ: PRF incorporates a fibrin-rich matrix that may influence how growth factors release over time, distinguishing it from standard PRP preparations. Current evidence does not establish that PRF consistently produces better or longer-lasting facial rejuvenation results than PRP. A 2025 systematic review in the Journal of Cosmetic Dermatology reported that PRF may improve texture, wrinkles, and crepiness, while PRP showed stronger evidence for hyperpigmentation.

Exosome boosters represent a newer category that warrants closer scrutiny, as these cell-derived products can vary considerably in source, composition, purity, and manufacturing quality depending on the supplier. Exosome-based therapies have not received FDA approval for dermatologic use, and a 2026 expert review published by Wiley noted that long-term safety data remain limited. Patients are advised to confirm the exact product, its intended application, and regulatory status before proceeding.

RF microneedling takes a different approach, combining fine needles with radiofrequency energy to stimulate collagen remodeling in deeper skin layers. The FDA has authorized RF microneedling devices to improve the appearance of facial acne scars, facial wrinkles, and abdominal scars in patients aged 22 and older. Temporary redness and swelling are common after treatment, while less frequent risks include burns, pigmentation changes, scarring, and unwanted fat loss; the FDA advises seeking a licensed provider trained in the procedure and asking which device will be used.

Lydian Clinic's educational materials note that combining treatments does not automatically lead to better outcomes, since each additional procedure carries its own costs and considerations. The clinic discusses how PRP, PRF, exosome boosters, and RF microneedling might be incorporated into a personalized treatment plan, with suitability for any specific combination confirmed directly with the clinic.

An informed comparison of these options, rather than the number of procedures selected, supports appropriate decision-making for visitors weighing skin-rejuvenation choices in Seoul. Further details on the clinic's approach to these treatments are available at https://www.lydianclinic.com/

Contact Info:
Name: Dr. Abraham An
Email: Send Email
Organization: Lydian Cosmetic Surgery Clinic
Address: 836 Nonhyeon-ro, Sinsa-dong, Gangnam, Seoul, Seoul 06025, Korea, Republic of
Phone: +82-10-9692-5508
Website: https://www.lydianclinic.com/

Source: NewsNetwork

Release ID: 89207233

Should you come across any errors, concerns, or inconsistencies within this press release's content, we urge you to reach out without delay by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our committed team will promptly address your feedback within 8 hours and take appropriate measures to resolve any identified issues or guide you through the removal process. Providing accurate and dependable information remains our utmost priority.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  248.00
-2.38 (-0.95%)
AAPL  347.73
-0.50 (-0.14%)
AMD  516.79
+8.86 (1.74%)
BAC  50.56
-0.52 (-1.02%)
GOOG  317.28
-3.48 (-1.08%)
META  642.62
-6.23 (-0.96%)
MSFT  524.51
+3.43 (0.66%)
NVDA  210.96
-1.25 (-0.59%)
ORCL  126.16
+0.62 (0.49%)
TSLA  372.22
-2.36 (-0.63%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.